bluuebunny/crossref_metadata_2025_split huggingface dataset:
The comparison of OCT findings and retinal artery diameter in good and poor prognosis RAO patients
Authors: PARK J , JO S , LEE S 
Published: August 2014

AbstractPurpose To determine the different clinical findings between good and poor prognosis group which is diagnosed with branch retinal artery obstruction(BRAO) and treated with conservative care. We evaluate the average macular thickness, foveal thickness, outer nuclear layer(ONL) on optical coherence tomography(OCT) and retinal artery diameter in both groups.Methods 9 eyes(9 patients) in patients with non‐complicated BRAO with good prognosis and a poor prognosis control group with non‐complicated BRAO of 11 eyes(11 patients) were used in this study. The average macular thickness, foveal thickness and ONL thickness at the center of fovea on OCT were measured. And branch retinal artery widths were measured by a semi‐automated retinal vessel width measurement system retrospectively.Results The average age of the patients was 67.3 ± 11.5 years. The average ONL thickness at the central fovea of the good prognosis group was significantly thicker than that of the control group (p = 0.016). There were no statistically significant result at average macular thickness and foveal thickness. In good prognosis group, Ischemic retinal artery diameter and Central retinal artery equivalent(CRAE) were wider than those of poor prognosis group and they were statistically significant (p = 0.028, p = 0.01).Conclusion In the patients diagnosed with BRAO and treated with conservative care, foveal thickness, ischemic retinal artery diameter and CRAE were statistically significant between good and poor prognosis groups. In the patients diagnosed with BRAO, foveal thickness and retinal artery diameter could be prognostic factors that predict visual prognosis.
Can Ozurdex® make the difference in a retinal vein occlusion population with longstanding macular edema and multiple prior treatments?
Authors: VAN CALSTER J 
Published: August 2014

AbstractPurpose To evaluate the efficacy and safety of Ozurdex® in the treatment of macular edema (ME) due to retinal vein occlusion (RVO) in a difficult‐to‐treat population with multiple prior treatments and long‐standing MEMethods In this multicentric, anonymised, retrospective data collection, 77 patients were included during the early access program in Belgium. 46 patients had CRVO (59.7%) and 31 had BRVO (40.3%).Results The mean time between the diagnosis of RVO and the first Ozurdex® injection was 1.91±2.13 years, with a median time of 1.26 (0.03 – 10.57) years. In 55.8%, this interval was more than one year. Concerning prior treatments before the first Ozurdex® injection, 55 patients (71%) did receive one or more anti‐VEGF injections, 24 patients (31%) did receive one or more Triamcinolone injections and 33 patients (43%) underwent laser treatment (panretinal/focal). A total of 40 (52%) patients showed 2 line improvement and 29 (38%) showed 3 line improvement in BCVA (ETDRS letters). Nine (11.6%) patients underwent cataract surgery. Post‐injection, 14 (18%) patients had an IOP >25 mmHg. There was no need for glaucoma surgery.Conclusion In this difficult‐to‐treat population with multiple prior treatments and long‐standing ME, Ozurdex® has shown to be efficacious. The safety profile is in line with previously reported trials. Larger prospective observational studies are currently underway to clarify the usage patterns of Ozurdex® in clinical practice.
Inhibition of NO and COX products modifies the hypoxia‐induced dilatation of retinal vessels in vivo
Authors: KAYA M , PEDERSEN L , BEK T 
Published: August 2014

AbstractPurpose Retinal hypoxia with consequent changes in blood perfusion is a central feature in common vision threatening diseases. The aim of this study was to examine the effects of inhibiting COX and NO‐synthesis on hypoxia‐induced relaxation of retinal vessels in humansMethods Twenty healthy persons aged 20‐55 years were examined on two days separated by 4‐7 days. The resting diameter and the diameter response to isometric exercise and flicker stimulation of retinal vessels were studied using the Dynamic Vessel Analyzer before and during breathing a hypoxic gas mixture and before and during intravenous infusion with the NOS inhibitor L‐NMMA and were repeated on a second day after topical administration of the COX‐inhibitor diclofenacResults The resting diameter of arterioles increased significantly during hypoxia and decreased significantly during L‐NMMA infusion (p<0.0001) whereas no change in diameter was observed with the two applied together. When hypoxia and L‐NMMA were applied simultaneously, the gain factor was significantly lower than 1 (p=0.002) indicating that when diameter changes were corrected for changes in arterial blood pressure the blood flow increased, whereas this was not the case for either of the two interventions alone. Diclofenac significantly reduced contraction of retinal arterioles induced by isometric exercise (p=0.04) but not by the other interventions. Flicker‐induced dilatation of retinal arterioles was increased during L‐NMMA infusion (p<0.0001) but not during the other interventionsConclusion Diameter changes of retinal vessels during hypoxia are influenced by NO and COX products. This may point to new treatment strategies for diseases characterized by retinal hypoxia and disturbances in retinal perfusion
Diabetic retinopathy: A descriptive study of a method of investigation: BOA’s project
Authors: BAZIN L 
Published: August 2014

AbstractPurpose The purpose of this study is to report the results of 208 patients observation comparing two different interfaces of delayed reading retinophotographies and thus two different logistics managements of diabetic patients at the University Hospital of BrestMethods Prospective study of 208 diabetic patients followed. Retinophotographies were automatically and randomly assigned to one of two consoles for delayed reading by an ophthalmologist.The « examination time » and « writing report time » were identified. The settings « diagnosis », « image quality » and «follow‐up » were graduatedResults 208 patients were included.The examination time did not differ between the two consoles (Student t test: t = 0.623, p = 0.534). « Writing report time » differ a statistically significant manner (p << 10‐4).There is a positive correlation between « examination time » and « writing report time » (r = 0.382, p <10‐4) for both consoles. There are no statistically significant differences in the « image quality » setting between the two systems (p = 0.623). There was no statistically significant difference between the two consoles on the variables « follow‐up » (p = 0.067)Conclusion There is a positive correlation between « examination time » and « writing report time » (r = 0.382, p <10‐4) for both consoles. There are no statistically significant differences in the « image quality » setting between the two systems (p = 0.623). There was no statistically significant difference between the two consoles on the variables « follow‐up » (p = 0.067)
Effects of combination of antioxidants and omega 3 fatty acids in diabetic retinopathy
Authors: SANTANDER‐TRENTINI F , VIVAR‐LLOPIS B , CHAQUES‐ALEPUZ V , ALONSO L , ZANON‐MORENO V , GALLEGO‐PINAZO R , DOLZ‐MARCO R , SHOAIE‐NIA K , PINAZO‐DURAN MD 
Published: August 2014

AbstractPurpose Oxidative stress is a relevant pathogenic factor in the development of diabetic retinopathy (DR). We evaluated whether the combination of antioxidants and omega 3 fatty acids (A‐O3FA) would reduce the biochemical parameters of risk for diabetic complications in patients with type 1 (T1) and 2 (T2) diabetes mellitus (DM) who were vulnerable to vitreoretinal disorders.Methods A prospective case‐control study was carried out in 400 initial participants of both sexes aged 15 to 80 years that were distributed into three groups: 1) T1DMG (n=80), 2) T2DMG (n=220), and 3) healthy controls (CG; n=100). We randomly assigned half participants of each group to be orally supplemented (+OS) with 1 pill/day of open‐label formulation containing A‐O3FA, during one year of follow‐up. Demographics, nutrition, life style, ocular and blood biochemical data were recorded and statistically processed by the SPSS 15.0 program.Results Best‐corrected visual acuity did not vary during the follow‐up, irrespective of supplementation. Diabetics showed severer glycosilated haemoglobin, lipid profile, homocysteine and C‐reactive protein levels than the CG. Plasmatic malondialdehyde (MDA) (p< 0,01), total antioxidant activity (TAA) (p< 0,001) and glutathione (GSH) (p< 0,01) levels were significantly higher in T1DMG/T2DMG than in the CG. All these parameters noticeably changed in the supplemented groups. No significant variations were detected in the ocular coherence tomography examinations regarding three macula parameters, and no correlation with the biochemical data was found.Conclusion The biochemical background in DM creates the optimal conditions for the increased oxidative stress that can be minimized by the appropriate combination of A‐O3FA. Plasmatic homocysteine, C‐reactive protein, MDA, TAA and GSH can be presumptive biomarkers for DR.
Results from the treatment of refractory diabetic macular oedema with Bevacizumab in a clinical setting
Authors: PAPANDREOU I , TING M , MENSAH E 
Published: August 2014

AbstractPurpose To evaluate the outcome of the treatment of patients with refractory diabetic macular oedema with intravitreal bevacizumab (Avastin).Methods Prospective data was entered into an in house database of all patients being treated for refractory diabetic macular oedema at the Ophthalmology Department, Central Middlesex Hospital, London, UK. All patients received bevacizumab on a pro re nata basis after an initial loading phase of three injections. Best corrected visual acuity (BCVA) on the logMAR chart and the central retinal thickness (CRT) on the optical coherence tomography (OCT) scan were recorded at each visit. OCT was performed with the Spectralis OCT device (Heidelberg Engineering, Heidelberg, Germany) using the standard protocol of the clinic. Statistical analysis involved the Wilcoxon signed rank test and Spearman correlation test.Results 64 eyes of 48 patients were included in this study. The mean age was 68 years (range 45 ‐ 87). Patients received a mean of 3 bevacizumab (range 1‐10) injections. The follow‐up time was up to 15 months. The mean logMAR BCVA at baseline for Avastin was 0.74. At 2, 3, 7, and 11 months the mean BCVA was 0.77, 0.75, 0.67, and 0.69 respectively (p=0.01, 0.006, 0.02 and 0.05). There was no significant difference between baseline and any period thereafter during follow‐up to 15 months. Mean CRT at baseline was 527μm. The mean CRT at months 1‐4 were 456, 491, 490 and 480μm respectively and were significantly different for baseline, (p=0.001, 0.01, 0.03 and 0.04). CRT for months 5 to 15 were not significantly different from baseline.Conclusion The treatment of refractory diabetic macular oedema with intravitreal bevacizumab made little difference to improving the BCVA and CRT of the patients.
Antiangiogenic effect of ALS‐L1023 on experimental choroidal neovascularization in mice
Authors: KANG S , RHO YJ 
Published: August 2014

AbstractPurpose This study was conducted to evaluate the effect of ALS‐L1023 on experimental choroidal neovascularization (CNV) in mice.Methods C57BL/6 mice were administered either vehicle or ALS‐L1023 daily by oral gavage for three weeks (day 0‐21). CNV was induced in each mouse by rupturing Bruch’s membrane using laser photocoagulation (day 7). Two weeks after laser injury (day 21), the CNV lesions were evaluated by choroidal flat mounts using fluorescein‐labeled dextran, immunofluorescence staining with isolectin IB4, and fluorescence angiography. The effects of ALS‐L1023 on endothelial cell tube formation and on the expression of phosphorylated extracellular signal‐regulated kinase (p‐ERK1/2) were evaluated using human umbilical vein endothelial cells (HUVECs).Results ALS‐L1023 reduced the extent of CNV. The groups treated with 100 and 200 mg/kg/day showed 43.3 and 68.1 % reduction of CNV lesions, respectively, compared to the vehicle group (P < 0.001). The size of isolectin IB4 labeled area was also significantly decreased in the ALS‐L1023‐treated group (P < 0.001). On fluorescein angiography, ALS‐L1023‐treated mice had significantly less fluorescence leakage than vehicle‐treated mice. ALS‐L1023 decreased VEGF‐stimulated tube formation of HUVECs in a dose‐dependent manner. The expression of p‐ERK was suppressed by ALS‐L1023.Conclusion ALS‐L1023 can inhibit laser‐induced CNV in mice and may have therapeutic potential for treatment of choroidal neovascularization diseases.
Evaluation of two methods for measurements of macular pigment optical density (MPOD)
Authors: BIRKELDH U , WAHLBERG RAMSAY M , NILSSON M , BRAUTASET R 
Published: August 2014

AbstractPurpose To evaluate the outcomes of two methods for measurements of macular pigment optical density (MPOD).Methods In 33 subjects (mean age 51.85 years ±17.79; 4 men and 29 women), without any signs of ocular pathologies, MPOD was measured in the right eye using single‐wavelength reflectometry (Visucam 500) and heterochromatic flicker photometry (MacuLux®). In 13 subjects with discrete signs of age‐related macuolopathy (ARM), i.e., soft drusen and/or hyper‐/hypopigmentation of the retinal pigment epithelium (RPE), MPOD was measured after 6 and 12 methods of supplementation with MacuShield® (lutein 10 mg and zeaxanthin 2 mg and the non‐dietary carotenoid meso‐zeaxanthin 10 mg).Results There was a statistical significant difference (p<0.001) between the average maximum MPOD in the healthy subjects measured with the Visucam (0.384 ±0.049) and with the Maculux® (0.559 ±0.133). No correlation (r2= 0.089, p=0.09) was found between the two techniques. In the 13 subjects, treated with Macushield, the Visucam measurements showed a statistically significant MPOD reduction (p<0.0005) while a significant increase (p<0.0045) in MPOD was found with the MacuLux®.Conclusion The results from this study indicate that measurements of MPOD with different techniques do not correlate and that the Visucam seems unable to detect the increase in macular pigment after intake of supplementation.
Method for comparative evaluation of therapeutic efficacy in dry AMD patients using 3D‐CTAG
Authors: MILYUTKINA S , FINK W , KOVALEVSKAYA M 
Published: August 2014

AbstractPurpose Evaluation of therapeutic efficacy in dry AMD patients using 3DComputer‐automated Threshold Amsler Grid testing (3D‐CTAG; Fink &Sadun, 2004).Methods Dry AMD patients (n=87, 174 eyes). Group#1 (n=29): 200 mg Docosahexaenoic Acid (DHA) and 300 mg Eicosapentaenoic Acid (EPA). Group #2 (n=29): Lutein (12 mg) and Zeaxanthin (0,5 mg). Controls (n=29). 3D‐CTAG testing after 3 months of treatment.Indices: number of VF defects per eye (ND),lowest perceivablecontrast level (CL), absolute volume lost (AVL), VF volume lost relative to hill‐of‐vision (VLRH).Results Group#1: ND=0,31±0,54 (before) down to 0,16±0,37(after treatment); CL=12,31±8,03% down to 10,9±7,21%; VLRH=1,2±1,14% down to 0,26±0,52%.Group#2: ND=0,29±0,5 down to 0,21±0,41; CL=11,72±12,79% down to 9,66±10,2%; VLRH=1,01±0,88% down to 0,68±1,14%. Controls: ND=0,29±0,5 up to 0,34±0,51; CL=13,79±8,65% up to 14,38±10,38%; VLRH=0,93±0,9% up to 1,22±1,21%.Conclusion We demonstrated with 3D‐CTAG a decrease of VLRH of 0,94% (p=0,01) in group#1 after 3 months DHA/EPA treatment compared to 0,33% (p=0,05) in group#2, and an increase of VLRH of 0,29% (p=0,01) in the controls. This seems to indicate that DHA/EPA treatment of dry AMD may be more effective than Lutein‐Zeaxanthin therapy.
Commercial interest
Relation between subfoveal choroidal thickness and visual acuity in patients with wet and dry age‐related macular degeneration
Authors: ZABADANI K , HERRERA L , ASCASO FJ , CARAMELLO C , ALMENARA C , PEREZ NAVARRO I , MARTINEZ M , ESTEBAN O , PADGETT E , CABEZON L , CRUZ N , CRISTOBAL J 
Published: August 2014

AbstractPurpose To evaluate the relationship between best‐corrected visual acuity (BCVA) and subfoveal choroidal thickness (SCT) in patients with wet and dry age‐related macular degeneration (AMD).Methods We investigated 63 eyes of 58 patients who were diagnosed with wet AMD, and 69 eyes of 56 patients who were diagnosed with dry AMD. All patients were evaluated in the Department of Ophthalmology at the “Lozano Blesa” University Clinic Hospital, Zaragoza, Spain, between January and October 2013. SCT was measured by using enhanced depth imaging (EDI) in spectral domain optical coherence tomography (SD‐OCT).Results The mean age of patients was 80.2 ± 5.9 year and 81.1 ± 5.2 years in patients with wet and dry AMD respectively (p>0.05, t student test). BCVA was 20/100 and 20/40, in patients with wet AMD and dry AMD, respectively (p<0.001, t student test). Mean SCT was 151.1 ± 73.5 µm and 155.6 ± 55.1 µm, in wet AMD and dry AMD patients, respectively (No statistically significant differences, p>0.05). Wet AMD patients showed a positive and statistically significant correlation between SCT and BCVA (r=0.298, p=0.018). Nevertheless, patients diagnosed with dry AMD showed no relationship between SCT and BCVA (r=0.085, p=0.488).Conclusion BCVA is positively correlated with SCT in patients diagnosed with wet AMD. No correlation was observed between both parameters in patients with dry AMD.
AMD Drusenoid deposits “Lipid Type” characteristics and evolution. Multimodal imaging evaluation
Authors: GONZALEZ C 
Published: August 2014

AbstractPurpose To study AMD drusenoid deposits “Lipid Type” evolution with multimodal imaging. To individualize their evolution and complication and to consider various etiopathogenic AMD optionsMethods 98 eyes of 49 patients, 18 men, 31 women, with AMD. AMD drusenoid deposits, “Lipid type”: soft Drusen, Drusenoid PED (lipid type), were evaluated by Autofluorescence, IR imaging, ETDRS visual acuity (VA), ocular Fundus examination, Ocular Confocal Tomography exam (OCT), OCT en Face software (Spectralis HRA‐OCT). Size, characteristics, number, topography of the lesions, growth were evaluated, as well as their environment above and below. With OCT, each element was studied, compared cut to cut, layer to layer and time to time to itself and to each other data. Follow‐up was done every 4 months during 2 yearsResults Soft drusen were larger, roughly homogenous, dark‐grey, translucent, dome‐shaped mounds of deposit under the RPE; Drusenoid PED, lipid type, were homogeneous, as convergence of soft drusen, dark‐grey. Multimodal imaging, especially OCT, OCT en Face features let individualize “lipid type” drusenoid deposits: morphologic types appearing homogeneous, dark, optically empty, fatty. Evolution change, depend on those characteristics, rather to IS/OS impairment, photoreceptor disappearance, RPE involution, and so atrophy. They seem result from a specific metabolic defect outcome, peculiar etiopathogenic pathways: lipid metabolic pathway disorder with particular metabolic dysfunctions inrolled. Furthermore, lipid type drusenoid deposits’ prognostic, predictive value allow to designate them for biomarker featureConclusion AMD Drusenoid deposits “lipid type” knowledge, evolution allow better AMD metabolism dysfunction understanding and etiopathogenic concept
Management of choroidal neovascularisation in late onset retinal degeneration
Authors: WIRYASAPUTRA S , YONG SO 
Published: August 2014

AbstractPurpose Late onset retinal degeneration is a hereditary condition characterized by progressive difficulty in dark adaptation and risk of choroidal neovascularisation. This in turn leads to a marked decline in visual acuity. We describe our experience treating a patient with a positive family history of late onset retinal degeneration who developed subfoveal choroidal neovascularisation.Methods Case report. A 57 year old Caucasian lady with a positive family history of late onset retinal degeneration and progressive decline in dark adaptation presented to us with a 1‐week history of blurring of vision. Fundus fluorescein and indocyanine green angiography revealed a subfoveal classic neovascular membrane.Results Our patient was initially treated with intra‐vitreal Ranibizumab and clinical activity of neovascularisation was monitored with serial spectral domain optical coherence tomography and visual acuity. Serial scans revealed recurrence of activity within a month of intra‐vitreal Ranibizumab. With the advent of intra‐vitreal Aflibercept, we offered our patient a change in treatment regime. Treatment with Aflibercept has thus far demonstrated a stabilization of disease activity on spectral domain optical coherence tomography and visual acuity for at least 8 weeks.Conclusion Whilst Ranibizumab and Aflibercept remain off‐label for the treatment of late onset retinal degeneration, this suggests that Aflibercept is possibly more efficacious in the management of choroidal neovascular membranes in late onset retinal degeneration.
Intravitreal anti‐VEGF in submacular hemorrhage due to age related macular degeneration
Authors: DESSERRE J , LABALETTE P 
Published: August 2014

AbstractPurpose To evaluate efficacy and prognostic factors of intravitreal anti‐VEGF for large submacular hemorrhage (HSM) secondary to age‐related macular degeneration (AMD).Methods Eighteen eyes of 18 patients with HSM neovascular AMD were reviewed. HSM had to respect a diameter greater than three papillary disk diameters and with fovea participation. Visual acuity was considered at diagnosed and when best final visual acuity was achieved. HSM outcomes were measured by SD‐OCT. Statistical analysis was used to evaluate association between visual acuity and different outcomes: macular status of fellow eye, hemorrhagic surface, hemorrhage localization, central foveal thickness, highest macular thickness and macular volume.Results Mean duration of symptoms was 25.94 +/‐ 32 days. Mean anti‐VEGF injection was 3.31 +/‐ 0.3. Mean hemorrhagic surface was 8.77 +/‐ 6.52 disc areas. 62 % patients presented their first exudative episode. The mean logMAR visual acuity improved from 1.5 +/‐ 0.52 to 1.0 +/‐ 0.40 at final examination (p=0.04). A gain of three EDTRS lines or more was found in 50% patients. No association was evident between opposite side status, hemorrhagic surface and initial central fovea thickness with final visual acuity. Although an association between highest macular thickness, macular volume (p 0.05) and final visual acuity was significant. Patients with predominant sub‐retinal pigment epithelial hemorrhage seemed to have a worst visual prognosis.Conclusion Anti‐VEGF therapy is a useful treatment for large HSM. In our study, highest macular thickness and macular volume at diagnosis seem more predictive than central fovea thickness or hemorrhagic surface. Factor prognosis need to be clearly identify to select patients for surgical procedures.